demonstrated significant tumor growth inhibition in BRAF inhibitor (BRAFi)-resistant colorectal cancer when FAK inhibitors (FAKi) were combined with RAF/MEK inhibitors (RAFi/MEKi). This evidence concerns the gene BRAF and neoplasm.